These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38265606)

  • 61. A new era in patent foramen ovale closure - a percutaneous suture-based 'deviceless' technique (NobleStitch®): Experience of a Portuguese center.
    Neto A; Resende CX; Tavares Silva M; Silva JC; Macedo F
    Rev Port Cardiol; 2023 Jan; 42(1):53-59. PubMed ID: 36116990
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Patent foramen ovale closure with the Intrasept occluder: Complete 6-56 months follow-up of 247 patients after presumed paradoxical embolism.
    Spies C; Timmermanns I; Reissmann U; van Essen J; Schräder R
    Catheter Cardiovasc Interv; 2008 Feb; 71(3):390-5. PubMed ID: 18288745
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Safety and efficacy of Cardi-O-fix occluder for percutaneous closure of a patent foramen ovale: A single-center prospective study.
    Zhao E; Liu W; Zhang Y; Cheng G; Du Y; He L; Wang X; He X
    Medicine (Baltimore); 2017 Apr; 96(14):e6572. PubMed ID: 28383438
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.
    Rengifo-Moreno P; Palacios IF; Junpaparp P; Witzke CF; Morris DL; Romero-Corral A
    Eur Heart J; 2013 Nov; 34(43):3342-52. PubMed ID: 23847132
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficiency of transcatheter patent foramen ovale closure in children after paradoxical embolism events.
    Wawrzyńczyk M; Gałeczka M; Karwot B; Knop M; Białkowski J
    Kardiol Pol; 2016; 74(4):385-9. PubMed ID: 26412471
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.
    Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC
    Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long-Term Outcome After Percutaneous Closure of Patent Foramen Ovale for Cryptogenic Ischemic Events.
    Seeger J; Uber A; Wöhrle J
    J Invasive Cardiol; 2019 Aug; 31(8):E242-E248. PubMed ID: 31368895
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Patent foramen ovale (PFO) closure versus medical therapy for prevention of recurrent stroke in patients with prior cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials.
    Akobeng AK; Abdelgadir I; Boudjemline Y; Hijazi ZM
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):165-173. PubMed ID: 29602258
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Association between patent foramen ovale morphology and clinical outcomes following transcatheter closure.
    Sun L; Fan Z; Gao J; Zhao T; Si J; Zhang H; Li Y; Sun J; Wang X; Liu Z; Yi M; Hua Y; Xing Y; Liu Z; Li J
    Int J Cardiol; 2024 Oct; 412():132307. PubMed ID: 38945369
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The role of device closure of patent foramen ovale in patients with cryptogenic stroke.
    Fukutomi M; Wilkins B; Søndergaard L
    J Intern Med; 2020 Oct; 288(4):400-409. PubMed ID: 32812297
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Anatomical predictors for suture-based closure of the patent foramen ovale: A multicenter experience.
    Witte LS; Renkens MPL; Gąsecka A; El Bouziani A; de Winter RJ; Tijssen JGP; Stella PR; Leibundgut G; Voskuil M
    Catheter Cardiovasc Interv; 2023 Aug; 102(2):273-280. PubMed ID: 37221985
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Incidence and Outcomes of Positive Bubble Contrast Study Results After Transcatheter Closure of a Patent Foramen Ovale.
    Shah AH; Osten M; Benson L; Alnasser S; Bach Y; Vishwanath R; Van De Bruaene A; Shulman H; Navaranjan J; Khan R; Horlick E
    JACC Cardiovasc Interv; 2018 Jun; 11(11):1095-1104. PubMed ID: 29880106
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Transcatheter closure of patent foramen ovale: Current evidence and future perspectives.
    Akagi T
    J Cardiol; 2021 Jan; 77(1):3-9. PubMed ID: 33144025
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Long-term experience and outcomes with transcatheter closure of patent foramen ovale.
    Inglessis I; Elmariah S; Rengifo-Moreno PA; Margey R; O'Callaghan C; Cruz-Gonzalez I; Baron S; Mehrotra P; Tan TC; Hung J; Demirjian ZN; Buonanno FS; Ning M; Silverman SB; Cubeddu RJ; Pomerantsev E; Schainfeld RM; Dec GW; Palacios IF
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1176-83. PubMed ID: 24262618
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Patent foramen ovale closure in the management of cryptogenic stroke: a review of current literature and guideline statements.
    Elzanaty AM; Patel N; Sabbagh E; Eltahawy EA
    Curr Med Res Opin; 2021 Mar; 37(3):377-384. PubMed ID: 33460329
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Patent foramen ovale closure with the Occlutech Figulla flex II device: A long-term (up to 10-years) follow-up.
    Trabattoni D; Gili S; Calligaris G; Teruzzi G; Troiano S; Ravagnani P; Santagostino Baldi G; Montorsi P
    Int J Cardiol; 2023 Sep; 387():131116. PubMed ID: 37301447
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Is Moderate/Large Residual Shunt After PFO Closure Justifiable for a Patient with a Prior History of Cryptogenic Stroke and Transient Ischemic Attack?
    Melillo F; Popusoi G; Frecentese F; Miano V; Santoro A; Tesorio T; Onorato EM
    Int Heart J; 2024; 65(1):146-151. PubMed ID: 38296568
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of Outcomes after Device Closure with Transseptal Puncture and Standard Technique in Patients with Patent Foramen Ovale and Ischemic Events.
    Moon J; Kang WC; Kim S; Kim MG; Oh PC; Park YM; Chung WJ; Choi DY; Lee JY; Lee YB; Hwang HY; Ahn T
    J Interv Cardiol; 2016 Aug; 29(4):400-5. PubMed ID: 27282763
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Recurrent events after percutaneous closure of patent foramen ovale.
    Wallenborn J; Bertog SC; Franke J; Steinberg DH; Majunke N; Wilson N; Wunderlich N; Sievert H
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):541-6. PubMed ID: 22707325
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A matching-adjusted indirect comparison of results from REDUCE and RESPECT-two randomized trials on patent foramen ovale closure devices to prevent recurrent cryptogenic stroke.
    Kasner SE; Sondergaard L; Nakum M; Gomez Montero M; Hashim M; Landaas EJ
    J Med Econ; 2024; 27(1):337-343. PubMed ID: 38373018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.